Columbia Asthma & Allergy

Allergist in OR, CA, & WA

  • Facebook
  • Pinterest
  • Twitter
888-586-6155
CALL 24 HOURS A DAY TO MAKE AN APPOINTMENT

  • Home
  • Shot Hours
  • Services
    • Services Overview
    • First Appointment
    • When to Refer
    • Systemic Allergic Conditions
      • Overview
      • Food Allergy and Associated GI Symptoms
      • Lymph Node Injections for Environmental Allergies
      • Oral Immunotherapy for Anaphylactic Food Allergies
      • Sublingual Immunotherapy for Food and Environmental Allergies
      • Evaluation and Treatment of Medication Allergies
      • Evaluation of Allergies to Dental and Orthopedic Reagents
    • Allergy-Related Conditions of the Nose and Sinuses
    • Asthma and Related Conditions
    • Allergy-Related Skin Conditions
    • Other Immunologic Conditions
    • General Info
  • Resources
    • Allergy Info
    • Links
  • Media/Press
    • Featured Media
    • News
  • Testimonials
  • Providers
  • Contact us
  • Blog
  • Research
    • Overview
    • About Portland Clinical Research
    • Immune Deficiencies
    • Heriditary Angiodema
    • Allergies
    • COPD
    • Asthma

COPD

Medical Condition:  Chronic Obstructive Pulmonary Disease (COPD)

Purpose of Study:  To evaluate the safety and effectiveness of benralizumab in patients with moderate to very severe COPD who have a history of COPD flare-ups

Eligibility Requirements:

  • 40 to 85 years old
  • History of moderate to very severe COPD
  • History of smoking

Treatment with an inhaled corticosteroid and at least one other controller medication for at least 12 months. Examples of medications that may qualify for the study include, but are not limited to Advair Diskus®, Symbicort®, Breo Ellipta®, Serevent®, Foradil®, Arcapta Neohaler®, Anoro Ellipta®, Spiriva HandiHaler®, and Tudorza Pressair® .

At least 2 COPD flare-ups in the past 12 months requiring treatment with a systemic corticosteroid and/or antibiotics. Examples of systemic corticosteroids include, but are not limited to prednisone, prednisolone, methylprednisolone, and dexamethasone.
OR
At least 1 COPD flare-up that required hospitalization in the past 12 months.

Compensation: Compensation will be provided.

Please contact Heather Kohler at 971-220-2208, extension 2, for additional information about the research study.

Contact Us

  • Facebook
  • Pinterest
  • Twitter

Facebook

Columbia Allergy & Asthma Clinic

Contact Us

  • (888) 586-6155
  • info@aa-clinic.com
  • fill in the form on contact page

Recent Posts

  • Visiting Columbia Asthma & Allergy Clinic for Relief
  • How Can Medication Help Relieve My Allergies?
  • 7 Benefits of Allergy Testing at a Clinic
© 2018 Crystal Clear Digital Marketing | Site Map | TOS/Privacy Policy | Columbia Allergy & Asthma Clinic